Ionis Pharmaceuticals IONS Ionis Operations — Selling General And Administrative Expense

Similar metrics at other companies

IQVOperating Segments — Selling General And Administrative Expense

$359M+12.5%

IES

IESCCorporate Segment — Selling, general and administrative expenses

$18.7M+56.6%

IES

IESCCommercial and Industrial — Selling, general and administrative expenses

$14.75M+33.8%

BBIOReportable Segment Aggregation Before Other Operating — Selling General And Administrative Expense

$129.15M+117%

IFFHealth & Biosciences — Selling and administrative expenses

$92M+13.6%

ALife Sciences and Diagnostics Markets — Selling, General and Administrative Expense

$170M+8.3%

Questions, answered.

What is Ionis Pharmaceuticals's ionis operations — selling general and administrative expense?

Ionis Pharmaceuticals (IONS) reported ionis operations — selling general and administrative expense of $131.94M in Q1 2026.

How has Ionis Pharmaceuticals's ionis operations — selling general and administrative expense changed year-over-year?

Ionis Pharmaceuticals's ionis operations — selling general and administrative expense increased by 97.0% year-over-year, from $66.98M to $131.94M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — selling general and administrative expense?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — selling general and administrative expense has grown at a 41.5% compound annual growth rate (CAGR), from $124.37M to $351.99M.

What does ionis operations — selling general and administrative expense mean?

General corporate overhead and commercialization costs for running the business.

How do you interpret ionis operations — selling general and administrative expense?

A decrease relative to revenue indicates improved operating leverage and administrative efficiency.

How does ionis operations — selling general and administrative expense compare across companies?

Comparable to SG&A expenses across all industries.